PL359727A1 - Crystalline pharmaceutical - Google Patents
Crystalline pharmaceuticalInfo
- Publication number
- PL359727A1 PL359727A1 PL35972701A PL35972701A PL359727A1 PL 359727 A1 PL359727 A1 PL 359727A1 PL 35972701 A PL35972701 A PL 35972701A PL 35972701 A PL35972701 A PL 35972701A PL 359727 A1 PL359727 A1 PL 359727A1
- Authority
- PL
- Poland
- Prior art keywords
- crystalline pharmaceutical
- crystalline
- pharmaceutical
- lopinavir
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53825700A | 2000-03-30 | 2000-03-30 | |
US09/793,536 US6608198B2 (en) | 2000-03-30 | 2001-02-27 | Crystalline pharmaceutical |
PCT/US2001/009112 WO2001074787A2 (en) | 2000-03-30 | 2001-03-21 | Crystalline pharmaceutical |
Publications (1)
Publication Number | Publication Date |
---|---|
PL359727A1 true PL359727A1 (en) | 2004-09-06 |
Family
ID=27065762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL35972701A PL359727A1 (en) | 2000-03-30 | 2001-03-21 | Crystalline pharmaceutical |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1268442A2 (ko) |
JP (1) | JP2003529592A (ko) |
KR (1) | KR100773258B1 (ko) |
CN (2) | CN1330639C (ko) |
AR (2) | AR033360A1 (ko) |
AU (3) | AU2001250920B2 (ko) |
BG (1) | BG107165A (ko) |
BR (1) | BR0109433A (ko) |
CA (1) | CA2403635A1 (ko) |
CZ (1) | CZ20023529A3 (ko) |
HU (1) | HUP0302675A3 (ko) |
IL (1) | IL151551A0 (ko) |
MX (1) | MXPA02009559A (ko) |
MY (1) | MY128296A (ko) |
NO (1) | NO325005B1 (ko) |
NZ (1) | NZ521183A (ko) |
PE (1) | PE20011232A1 (ko) |
PL (1) | PL359727A1 (ko) |
SA (2) | SA06270303B1 (ko) |
SK (1) | SK14832002A3 (ko) |
TW (1) | TWI284640B (ko) |
WO (1) | WO2001074787A2 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6608198B2 (en) | 2000-03-30 | 2003-08-19 | Abbott Laboratories | Crystalline pharmaceutical |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
WO2010089753A2 (en) * | 2009-02-06 | 2010-08-12 | Hetero Research Foundation | Novel polymorphs of lopinavir |
WO2011025849A1 (en) * | 2009-08-27 | 2011-03-03 | Merck Sharp & Dohme Corp. | Processes for preparing protease inhibitors of hepatitis c virus |
CN112830899A (zh) * | 2021-01-18 | 2021-05-25 | 合肥华方医药科技有限公司 | 一种洛匹那韦新晶型及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
WO1998057648A1 (en) * | 1997-06-16 | 1998-12-23 | Vertex Pharmaceuticals Incorporated | Methods of increasing the bioavailability of stable crystal polymorphs of a compound |
-
2001
- 2001-03-07 MY MYPI20011034A patent/MY128296A/en unknown
- 2001-03-21 PL PL35972701A patent/PL359727A1/xx not_active Application Discontinuation
- 2001-03-21 AU AU2001250920A patent/AU2001250920B2/en not_active Revoked
- 2001-03-21 CN CNB018076882A patent/CN1330639C/zh not_active Expired - Lifetime
- 2001-03-21 HU HU0302675A patent/HUP0302675A3/hu unknown
- 2001-03-21 CA CA002403635A patent/CA2403635A1/en not_active Abandoned
- 2001-03-21 CN CNA2007101123988A patent/CN101066952A/zh active Pending
- 2001-03-21 CZ CZ20023529A patent/CZ20023529A3/cs unknown
- 2001-03-21 KR KR1020027012849A patent/KR100773258B1/ko active IP Right Grant
- 2001-03-21 MX MXPA02009559A patent/MXPA02009559A/es active IP Right Grant
- 2001-03-21 EP EP01924250A patent/EP1268442A2/en not_active Withdrawn
- 2001-03-21 IL IL15155101A patent/IL151551A0/xx unknown
- 2001-03-21 JP JP2001572482A patent/JP2003529592A/ja active Pending
- 2001-03-21 BR BR0109433-5A patent/BR0109433A/pt not_active Application Discontinuation
- 2001-03-21 NZ NZ521183A patent/NZ521183A/en not_active IP Right Cessation
- 2001-03-21 WO PCT/US2001/009112 patent/WO2001074787A2/en active IP Right Grant
- 2001-03-21 SK SK1483-2002A patent/SK14832002A3/sk not_active Application Discontinuation
- 2001-03-21 AU AU5092001A patent/AU5092001A/xx active Pending
- 2001-03-29 AR ARP010101522A patent/AR033360A1/es not_active Application Discontinuation
- 2001-03-30 PE PE2001000299A patent/PE20011232A1/es not_active Application Discontinuation
- 2001-05-02 TW TW090107717A patent/TWI284640B/zh active
- 2001-08-07 SA SA06270303A patent/SA06270303B1/ar unknown
- 2001-08-07 SA SA01220270A patent/SA01220270B1/ar unknown
-
2002
- 2002-09-30 NO NO20024679A patent/NO325005B1/no not_active Application Discontinuation
- 2002-10-03 BG BG107165A patent/BG107165A/bg unknown
-
2005
- 2005-06-29 AR ARP050102702A patent/AR049560A2/es unknown
-
2006
- 2006-09-27 AU AU2006222711A patent/AU2006222711A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2003529592A (ja) | 2003-10-07 |
SA06270303B1 (ar) | 2009-08-02 |
TWI284640B (en) | 2007-08-01 |
HUP0302675A2 (hu) | 2003-12-29 |
KR100773258B1 (ko) | 2007-11-05 |
KR20030011807A (ko) | 2003-02-11 |
WO2001074787A2 (en) | 2001-10-11 |
NO20024679D0 (no) | 2002-09-30 |
AU5092001A (en) | 2001-10-15 |
NZ521183A (en) | 2004-03-26 |
AU2001250920B2 (en) | 2006-06-29 |
CN101066952A (zh) | 2007-11-07 |
WO2001074787A3 (en) | 2002-02-07 |
NO325005B1 (no) | 2008-01-14 |
AU2006222711A1 (en) | 2006-10-19 |
BR0109433A (pt) | 2004-08-10 |
AR049560A2 (es) | 2006-08-16 |
SK14832002A3 (sk) | 2003-02-04 |
PE20011232A1 (es) | 2001-12-08 |
MY128296A (en) | 2007-01-31 |
AR033360A1 (es) | 2003-12-17 |
CN1330639C (zh) | 2007-08-08 |
HUP0302675A3 (en) | 2004-03-29 |
CA2403635A1 (en) | 2001-10-11 |
IL151551A0 (en) | 2003-04-10 |
EP1268442A2 (en) | 2003-01-02 |
MXPA02009559A (es) | 2003-05-21 |
SA01220270B1 (ar) | 2006-11-14 |
NO20024679L (no) | 2002-09-30 |
CN1422259A (zh) | 2003-06-04 |
BG107165A (bg) | 2003-07-31 |
CZ20023529A3 (cs) | 2003-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP1718A (en) | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors | |
EA199900373A2 (ru) | Фармацевтические композиции | |
AU3652102A (en) | Compounds and their uses | |
IS6254A (is) | Lyfjasamsetningar sem innihalda HMG afoxunarensímlata | |
MY134136A (en) | Novel compounds comprising jak3 kinase inhibitors | |
MXPA03010134A (es) | Derivados de ciclohexan-1-4-diamina sustituidos. | |
DK1221277T3 (da) | Binaural synkronisering | |
MA26812A1 (fr) | Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases | |
MXPA02009706A (es) | Metodo para sintesis de perindopril y sus sales farmaceuticamente aceptables. | |
AU2001235691A1 (en) | Use of paullone derivatives for making medicines | |
GB0006133D0 (en) | Novel pharmaceutical | |
GB0017060D0 (en) | Production, stabilisation and use of reduced forms of pharmaceutical compounds | |
MY133969A (en) | Indoloquinazolinones | |
HK1045990A1 (en) | Novel derivatives and analogues of galanthamin. | |
AU2002232468A1 (en) | Pharmaceutical heterocyclic compounds | |
MXPA03000914A (es) | Sintesis de (r)-3-(4 -bromobencil) -1-(3, 5-diclorofenil) -5-yodo-3 -metil-1-h -imidazo[1, 2-a]imidazol -2-ona. | |
PL359727A1 (en) | Crystalline pharmaceutical | |
MXPA04004090A (es) | Compuestos substituidos de 1h-quinolin-2-ona. | |
AP2002002547A0 (en) | Calcilytic compounds. | |
FR2815332B1 (fr) | Devidoir suspendu, notamment pour cultures | |
EP1383511A4 (en) | CALCILYTIC COMPOUNDS | |
GB0021865D0 (en) | Novel pharmaceutical | |
DE60212130D1 (en) | Carvedilolpolymorph | |
GB0014006D0 (en) | Novel pharmaceutical | |
AU2001264900A1 (en) | Pharmaceutical use of fibulin-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |